[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acne-vulgaris\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acne-vulgaris":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,41,75,102,126,153,182,208,237,258,286,306,327,345,372,393,416,437,458,484,503,521,540,561,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644713","early-phase-1-comparison-of-topical-clascoterone-and-adapalene-for-mild-acne-vulgaris-100644713",false,"NCT07673094","Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris","Comparison of Efficacy of Topical Clascoterone With Topical Adapalene in the Treatment of Mild Acne Vulgaris","Inclusion Criteria:\n\n* Clinical diagnosis of mild acne vulgaris as per operational definition\n* Male or female patients\n* Age 12 to 35 years\n\nExclusion Criteria:\n\n* History of acne conglobata\n* History of acne fulminans\n* Use of topical anti-acne medications within the last 4 weeks\n* Use of systemic anti-acne therapy within the last 12 weeks\n* Known hypersensitivity or allergy to clascoterone or adapalene\n* History of eczema\n* History of rosacea\n* History of seborrheic dermatitis\n* History of psoriasis\n* Presence of active skin infections\n* Pregnant women\n* Lactating women","ALL","12 Years","35 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","There is no local data available regarding the comparative efficacy of topical clascoterone and topical adapalene, particularly in patients with mild acne vulgaris. The findings of this study will help dermatologists identify the more effective topical treatment for mild acne vulgaris, leading to improved patient outcomes and better utilization of healthcare resources. Furthermore, the study will contribute local data to the existing literature and may assist in developing evidence-based treatment recommendations for patients with mild acne vulgaris in our setting.\n\nPatients meeting the inclusion criteria from the Dermatology Unit, Khyber Teaching Hospital, MTI, Peshawar will be incorporated into the study following approval from the ethics committee. At the commencement of the trial, baseline demographics including gender, age, height, weight, BMI, duration of acne, socioeconomic status, profession, monthly income, education level and residential status will be documented. An elaborate explanation of the process involved in the study will be provided to the participants, and consent will be taken following an explanation of the pros and cons involved.\n\nRandomization will be performed by computer generated random list. The group assignments will be put into sealed envelopes, which will be opened when the patient will be included in study. 30 patients will be in topical clascoterone group (A) while 30 patients will be in topical adapalene group (B).\n\nPatients allocated to Group A will receive topical clascoterone 1% cream. It is required that they will clean their faces using a mild cleansing agent, dry their faces and thereafter apply a thin coating of clascoterone 1% cream to their whole face area in the morning and evening for 12 consecutive weeks.\n\nPatients allocated to Group B will receive topical adapalene 0.1% gel. Patients will cleanse the skin using a gentle cleanser, allow it to dry in the air for 10 minutes, and then apply one pea-sized amount of 0.1% adapalene gel over their entire affected area of the face once a day before going to bed for 12 weeks.",[28],"Acne Vulgaris","NOT_YET_RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":22},"2026-08-15",{"date":37,"type":22},"2027-08-22",{"name":39,"class":40},"Khyber Teaching Hospital","OTHER",{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100643557","phase-4-low-dose-versus-conventional-dose-oral-isotretinoin-for-acne-vulgaris-100643557","NCT07639073","Low-Dose Versus Conventional-Dose Oral Isotretinoin for Acne Vulgaris","Comparing the Efficacy and Safety of Low-Dose Oral Isotretinoin Versus Conventional-Dose in the Treatment of Acne Vulgaris","Inclusion Criteria:\n\n* Both genders\n* Age 18-45 years\n* Patients who are clinically diagnosed with moderate to severe acne vulgaris as per criteria defined in operational definition.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating\n* Patients with history of endocrine disorders such as PCOS etc. or having drug induced acne\n* Patients on corticosteroid treatment\n* Patients who have hypersensitivity to the isotretinoin\n* Patients who are taking any acne treatment\n* Patients with hyperlipidemia, chronic renal failure or liver failure","18 Years","45 Years",{"count":51,"type":22},164,[53],"PHASE4","Background and Purpose:\n\nAcne vulgaris is a common skin condition that can cause significant physical and emotional distress. Oral isotretinoin is a highly effective treatment for severe or persistent acne. While the standard (conventional) dose is effective, it is often associated with side effects like dry skin, chapped lips, and altered labs.\n\nThe purpose of this study is to compare a lower daily dose of oral isotretinoin against the conventional daily dose in individuals with acne vulgaris.\n\nWhat the Study Aims to Find Out:\n\nResearchers want to determine if a low-dose regimen can match the effectiveness (efficacy) of the conventional dose while reducing the frequency and severity of side effects (safety).\n\nStudy Design:\n\nParticipants will be randomly assigned to receive either the low-dose oral isotretinoin or the conventional-dose oral isotretinoin. Researchers will monitor and compare acne clearance rates, patient satisfaction, and any side effects experienced by the participants throughout the treatment period.",[28],[57,58,59,60,61,62,63],"Isotretinoin","Accutane","Acne Treatment","Dermatology","Low dose Isotretinoin","Conventional Dose Isotretinoin","Retinoids","2026-06-05",{"date":66,"type":33},"2026-06-10",{"date":68,"type":22},"2026-07",{"date":70,"type":22},"2026-10",{"name":72,"class":73},"Pakistan Institute of Medical Sciences","OTHER_GOV",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100550469","phase-3-clinical-trial-to-compare-oral-isotretinoin-to-standard-of-care-in-moderate-acne-skin-of-color-patients-100550469","NCT06447480","Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients","Randomized Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients: ETHNIC Study","ETHNIC","Inclusion Criteria:\n\n* Women and men between 13 and 30-year-old\n* Skin type IV, V and VI according to Fitzpatrick skin types\n* Moderate acne as defined by the French Society of Dermatology recommendations based on ECLA grading https:\u002F\u002Fdocument.sfdermato.org\u002Fgroupe\u002Fcentre-de-preuves\u002Flabel-recommandations-acne-post-college.pdf)\n* Patients must have a cell phone able to take selfies pictures with a minimum definition of 5Mb.\n* Signed informed consent\n* Affiliation to French social coverage.\n\nExclusion Criteria:\n\n* Mild and severe acne (ECLA grading : French recommendations) (https:\u002F\u002Fdocument.sfdermato.org\u002Fgroupe\u002Fcentre-de-preuves\u002Flabel-recommandations-acne-post-college.pdf)\n* Past cure of oral isotretinoin\n* Past cure of systemic antibiotics for acne in the last 6 months\n* Phototype I-III patients\n* Abnormal hemogram, liver enzyme, cholesterol, triglycerides at baseline\n* Pregnancy: female patient of childbearing potential will undergo a pregnancy test (plasmatic β-hCG)\n* Breast-feeding patients\n* Refusal of effective contraception for women\n* Contra-indications to oral isotretinoin, doxycycline, lymecycline, topical adapalene\u002Ftretinoin\n* Vulnerable people: adult under guardianship or deprived of freedom","13 Years","30 Years",{"count":86,"type":22},420,[88],"PHASE3","In Dermatology, assessment of people of color remains underrepresented in RCTs (\\\u003C10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420",[28],"RECRUITING","2026-05-18",{"date":94,"type":33},"2026-05-20",{"date":96,"type":33},"2025-04-29",{"date":98,"type":22},"2027-09-01",{"name":100,"class":40},"Centre Hospitalier Universitaire de Nice",19,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":74},"100533419","early-phase-1-weekly-isotretinoin-vs-tetracycline-for-moderate-acne-100533419","NCT06225570","Weekly Isotretinoin vs Tetracycline for Moderate Acne","Randomized Controlled Trial of Weekly Oral Isotretinoin vs. Oral Tetracyclines for the Treatment of Moderate Acne Vulgaris","Inclusion Criteria:\n\n\\- Male and Female patients, 12 years and older with a diagnosis of Moderate Acne Vulgaris\n\nExclusion Criteria:\n\n* Patients who are at baseline on long-term Tetracycline antibiotics, long-term Trimethoprim-Sulfamethoxazole, or on Spironolactone for any reason\n* Patients who have taken Isotretinoin in the past 6 months\n* Patients with hypersensitivity to Isotretinoin or to any of its components\n* Females who are pregnant, likely to become pregnant, or will be breast-feeding during the study period\n* Patients with a history of major depression, mania, or psychosis with an active episode during the past year including current psychotic symptoms and\u002For current suicidal ideation\n* Adult patients with cognitive impairment\n* Patients with baseline kidney or liver disease\n* Patients with baseline hypertriglyceridemia\n* Patients with history of or current pseudotumor cerebri\n* Patients with any clinically significant unstable medical condition which could pose a risk to the safety of the patient\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent",true,{"count":111,"type":22},50,[25],"In the effort to find better treatments for Moderate Acne, which often relies on long-term antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin A derivative, is highly effective for severe acne, its side effects limit its use for milder cases. A recent study from our institution investigated a new approach: weekly Isotretinoin dosing. The results were promising, with acne improvement and no major side effects. This suggests that weekly Isotretinoin could be a successful alternative for moderate acne in both males and females. To validate these findings, investigators propose a randomized controlled trial comparing weekly Isotretinoin to daily Doxycycline over four months. This study could confirm the safety and effectiveness of weekly Isotretinoin, as well as shed light on patient satisfaction, and long-term results compared to standard antibiotics. This research may offer a breakthrough in treating moderate acne while addressing concerns about antibiotic overuse.",[28],[116,117],"moderate acne vulgaris","isotretinoin","2026-05-15",{"date":92,"type":33},{"date":121,"type":33},"2025-02-01",{"date":123,"type":22},"2027-05",{"name":125,"class":40},"Medical University of South Carolina",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":109,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":74},"100634789","phase-4-comparing-sarecycline-and-doxycycline-effects-on-the-skin-and-gut-bacteria-in-acne-100634789","NCT07544251","Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.","The Effects of Sarecycline Versus Doxycycline on the Gut Microbiome and Skin Microbiome in Acne.","Inclusion Criteria:\n\n1\\) Diagnosis of acne vulgaris with:\n\n* At least 10 inflammatory lesions (papules, pustules, and nodules) up to 100 noninflammatory lesions (open and closed comedones)\n* No more than 2 nodules on the face\n\nExclusion Criteria:\n\n1. Dermatological condition of face or facial hair that could interfere with clinical evaluations\n2. Subjects who have used the following medications (topical refers only to the facial area) will not be eligible:\n\n2a) Within 2 week prior to randomization:\n\n* Topical acne medications such as retinoids, antibiotics, hormonal modulators\n* Topical benzoyl peroxide\n* Topical anti-inflammatories and corticosteroids\n\n  2b) Within 4 weeks prior to randomization:\n* Systemic antibiotics\n* Systemic acne treatments\n* Oral probiotic supplement\n* Systemic corticosteroids\n\n  2c) Within 12 weeks prior to randomization:\n* Systemic retinoids\n\n  3\\) Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.\n\n  4\\) Individuals who are pregnant or breastfeeding.\n\n  5\\) Individuals on oral contraceptive pills or progesterone or estrogen containing therapies unless they have been on a stable dose for 2 months.\n\n  6\\) Individuals on finasteride or dutasteride\n\n  7\\) Current tobacco smoker or a tobacco smoking history that is greater than 5 pack-years.","9 Years",{"count":135,"type":22},30,[53],"This study is being done to help better understand how the gut and skin bacteria of the body change when people with acne are treated with Sarecycline or Doxycycline. The bacteria in the gut and on the skin will be studied to see how each treatment may affect them and whether they change the profile of the bacteria that is present.",[28],[28,140,141,142],"Sarecycline","Doxycycline","Microbiome","2026-04-15",{"date":145,"type":33},"2026-04-22",{"date":147,"type":22},"2026-04-20",{"date":149,"type":22},"2027-06",{"name":151,"class":152},"Integrative Skin Science and Research","INDUSTRY",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":19,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":74},"100634395","investigating-the-efficacy-of-oral-probiotics-versus-placebo-in-pakistani-patients-with-moderate-acne-on-acne-lesion-count-and-systemic-inflammation-100634395","NCT07539129","Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation","A Randomized Controlled Trial Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation (Interleukin-6) Levels","Acne vulgaris","Inclusion Criteria:\n\n* Male and female patients aged 15-35 years\n* Clinical diagnosis of moderate acne vulgaris\n* Fitzpatrick skin types III-V\n* Willing to provide informed consent and comply with study protocol\n\nExclusion Criteria:\n\n* Severe nodulocystic acne, acne conglobata, or acne fulminans\n* Oral antibiotics, isotretinoin, or hormonal therapy within past 4 weeks\n* Topical anti-acne therapy within past 2 weeks\n* Current probiotic supplementation\n* Chronic inflammatory or autoimmune disease\n* Pregnancy or lactation","15 Years",{"count":163,"type":22},64,[165],"NA","This randomized controlled trial evaluates the efficacy of oral probiotics compared to placebo in Pakistani patients with moderate Acne Vulgaris. Acne is a multifactorial inflammatory disorder influenced by microbial colonization, seborrhea, and immune dysregulation. Rising antibiotic resistance necessitates alternative therapeutic approaches. Emerging evidence highlights the gut-skin axis, suggesting probiotics may reduce systemic inflammation and acne severity. A total of 64 patients will be randomized into probiotic and placebo groups and treated for 12 weeks. The primary outcome is reduction in total acne lesion count, while the secondary outcome is change in serum Interleukin-6 levels. Clinical assessment includes lesion counts, GAGS scoring, and standardized photography. IL-6 levels will be measured using ELISA at baseline and study completion. Data will be analyzed using SPSS with appropriate statistical tests, considering p ≤ 0.05 as significant. This study aims to provide evidence for probiotics as a safe, effective, and antibiotic-sparing option in acne management, particularly in South Asian populations.",[28],[28,169,170,171,172,173],"Modrate Acne","Probiotics","Inflammatory markers","Interleukin 6","Ecotec TM","2026-04-13",{"date":147,"type":33},{"date":177,"type":22},"2026-09-01",{"date":179,"type":22},"2027-08-01",{"name":181,"class":40},"Foundation University Islamabad",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":17,"minAge":133,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100633304","phase-4-study-to-assess-safety-pharmacokinetics-and-treatment-effect-of-cabtreo-100633304","NCT07524946","Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo","A 12-Week, Phase 4, Open-Label Study To Assess Safety, Pharmacokinetics, and Treatment Effect of CABTREO (Clindamycin Phosphate 1.2%, Adapalene 0.15%, and Benzoyl Peroxide 3.1%) Topical Gel In Pediatric Participants Ages 9 to 11 Years, 11 Month With Acne Vulgaris","Inclusion Criteria:\n\nA participant will be eligible for inclusion if he\u002Fshe meets all the following criteria:\n\n1. Male or female participants, ≥ 9 years of age and ≤ 11 years, 11 months of age at baseline\n2. Participants must provide verbal and signed, written informed consent; participants less than the age of consent must sign an assent for the study and a parent\u002Flegal guardian must sign the informed consent\n3. Participants must have a score of 3 (moderate) or 4 (severe) on the EGSS assessment at baseline\n4. Participants must have a facial acne inflammatory lesion (papules, pustules, and nodules) count ≥ 30 at baseline\n5. Participants must have a facial acne noninflammatory lesion (open and closed comedones) count ≥ 35 at baseline\n6. Participants must have acne lesions in at least 1 truncal region (ie, on the chest, back, and\u002For shoulder) at baseline\n7. Participants must have ≤ 2 facial nodules at baseline\n8. Women of childbearing potential and female participants who are premenses (≥ 9 years of age) must be willing to practice effective contraception for the duration of the study.\n\n   Effective contraception is defined as being stabilized on an oral contraceptive for at least 3 months; using an intrauterine device\u002Fsystem, condom with spermicide, diaphragm with spermicide, implant, NuvaRing®, injection, transdermal patch; bilateral tubal ligation; vasectomized partner; or practicing abstinence. Females on birth control pills must have taken the same type of pill for at least 3 months prior to entering the study and must not change types during the study. Those who have used birth control pills in the past must have discontinued use at least 3 months prior to the start of the study. Those who use birth control for acne control only should be excluded.\n9. Premenses females and women of childbearing potential must have a negative urine pregnancy test at screening and baseline, and must have a negative serum pregnancy test at screening.\n10. Participants must be willing to comply with study instructions and return to the study center for required visits; participants under the age of consent must be accompanied by the parent\u002Flegal guardian at the time of providing assent\u002Fconsent\n11. If a cleanser, moisturizer or sunscreen is needed during the study, participants must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer\u002Fsunscreen combination products; the participant must agree to use noncomedogenic products (including makeup and shaving products) Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study\n\nExclusion Criteria:\n\nA participant will not be eligible for inclusion if any of the following criteria apply:\n\n1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study\n2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, and\u002For eczema\n3. Any underlying disease(s) or other dermatological condition of the face that requires the use of interfering topical or systemic therapy, or makes evaluations and lesion counts inconclusive\n4. Participants with \\> 2 facial nodules at baseline\n5. Evidence or history of cosmetic-related acne\n6. Participants with a history of experiencing significant burning or stinging when applying any facial treatment (eg, makeup, soap, masks, washes, sunscreens) to the face\n7. Female participants who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study\n8. Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen) for less than 12 weeks immediately preceding study entry; a participant who is treated with estrogens for ≥ 12 consecutive weeks immediately prior to study entry need not be excluded unless the participant expects to change the dose, the drug, or discontinue estrogen use during the study\n9. If female, participant has a history of hirsutism, polycystic ovarian disease, or clinically significant menstrual irregularities\n10. History of regional enteritis, ulcerative colitis, inflammatory bowel disease, pseudomembranous colitis, chronic or recurrent diarrhea, or antibiotic-associated colitis\n11. Treatment of any type of cancer within the 6 months prior to screening, with the exception of complete surgical excision of skin cancer outside the treatment area\n12. Participant uses medications and\u002For vitamins during the study that are reported to exacerbate acne (azathioprine, haloperidol, Vitamin D, Vitamin B12, halogens such as iodides or bromides, lithium, systemic or topical mid- to super-high potency corticosteroids on the treatment area, phenytoin, and phenobarbital); multivitamins, including Vitamin A, at recommended daily doses, and Vitamin D at stable doses, are acceptable\n13. History of hypersensitivity or allergic reactions to any of the study preparations as described in the Investigator's Brochure, including known sensitivities to any dosage form of clindamycin phosphate, BPO, or adapalene\n14. Concomitant use of potentially irritating over the counter products that contain ingredients such as BPO, alpha-hydroxy acid, salicylic acid, retinol, or glycolic acids\n15. Participants who have not undergone the specified washout period(s) for the following topical preparations or physical treatments used on the face or participants who require the concurrent use of any of the following topical agents in the treatment area:\n\n    * Topical astringents and abrasives (including comedo removal strips) on the face -1 week\n    * Nonallowed moisturizers or sunscreens on the face -1 week\n    * Antibiotics on the face -2 weeks\n    * Other topical anti-acne drugs on the face -2 weeks\n    * Soaps containing antimicrobials on the face -2 weeks\n    * Anti-inflammatory agents and corticosteroids on the face -4 weeks\n    * Retinoids, including retinol, on the face -4 weeks\n    * Facial procedures, including chemical peel, microdermabrasion, light (eg, PDT, LED) and laser therapy, and acne surgery -4 weeks\n16. Participants who have not undergone the specified washout period(s) for the following systemic medications or participants who require the concurrent use of any of the following systemic medications:\n\n    * Corticosteroids (including intramuscular injections) (inhaled corticosteroids allowed) -4 weeks\n    * Antibiotics -4 weeks\n    * Other systemic acne treatments -4 weeks\n    * Systemic retinoids -6 months\n17. Participants who intend to use a tanning booth or sunbathe during the study\n18. Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function\n19. Participants who have any underlying disease the investigator deems uncontrolled, and that poses a concern for the participant's safety while participating in the study","11 Years",{"count":191,"type":22},100,[53],"This study is to evaluate the safety, pharmacokinetics, and treatment effect for topically applied CABTREO lotion in pediatric participants ages 9 to 11 years, 11 months with Acne Vulgaris.",[28],[196,197,198,28,199],"Pediatric","Open-Label","Cabtreo","Topical","2026-04-06",{"date":174,"type":33},{"date":203,"type":22},"2026-04",{"date":205,"type":22},"2027-12",{"name":207,"class":152},"Bausch Health Americas, Inc.",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":28,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":74},"100631756","phase-1-comparative-effectiveness-of-clindamycin-retinoid-clindamycin-retinoid-dexamethasone-and-10-sm-hucmsc-secretome-gel-in-the-improvement-of-mild-to-moderate-acne-vulgaris-100631756","NCT07504822","Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris","Comparative Effectiveness of Clindamycin-Retinoid, Clindamycin-Retinoid-Dexamethasone, and 10% SM-hUCMSC Secretome Gel in the Improvement of Mild-to-Moderate Acne Vulgaris: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Age 15-40 years.\n* Clinical diagnosis of mild to moderate acne vulgaris on the facial area.\n* Primary lesion location on the face, with a total lesion count meeting the above criteria.\n* Not currently using topical or systemic acne therapy within: the past 2 weeks for topical therapy; the past 4 weeks for systemic therapy (oral antibiotics, isotretinoin, or systemic steroids).\n* Willing to use only the treatment regimen provided by the investigators on the facial area throughout the study period.\n* Willing to adhere to the scheduled follow-up visits (weeks 0, 2, 4, and 8) and to sign informed consent.\n\nExclusion Criteria:\n\n* Presence of other facial skin diseases that may interfere with acne assessment (e.g., rosacea, contact dermatitis, impetigo, fungal infections, herpes, etc.).\n* History of hypersensitivity or allergy to clindamycin, retinoids, topical corticosteroids, or any components of the secretome gel.\n* Use of oral isotretinoin within the past 6 months.\n* Pregnancy or breastfeeding.\n* History of severe immunological disorders or uncontrolled systemic diseases (e.g., uncontrolled diabetes mellitus, severe liver or kidney disease).\n* Presence of extensive open wounds or active infections on the face.\n* Undergoing aggressive facial cosmetic procedures within the past 3 months (e.g., ablative laser, deep chemical peeling, dermabrasion).","40 Years",{"count":217,"type":22},189,[219,220],"PHASE1","PHASE2","The goal of this clinical trial is to etermine and compare the effectiveness of three therapeutic regimens for mild to moderate acne vulgaris, such as, clindamycin-retinoid combination, clindamycin-retinoid-dexamethasone combination, and sekretome SM-hUCMSC 10% gel. The main questions it aims to answer are :\n\n* Is there a change in the number of inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (open and closed comedones) before and after treatment in each treatment group?\n* Is there a difference in the reduction of acne vulgaris severity scores among the three treatment groups?\n* Are there differences in the rate of clinical improvement (time required to achieve a certain reduction in lesion count or severity score) among the treatment groups?\n* What are the incidence and characteristics of local adverse effects (erythema, burning sensation, skin dryness, irritation, hypo-\u002Fhyperpigmentation, and others) in each treatment group?\n* Are there differences in the impact of each therapeutic regimen on the risk of acne scar formation and improvement in skin quality (texture, elasticity, and color homogeneity)?\n* Does secretome gel demonstrate sufficient clinical potential and urgency as a safer and more prospective topical therapeutic alternative for acne vulgaris compared with retinol-clindamycin and retinol-clindamycin-dexamethasone 0.1% combinations?\n\nParticipants will be allocated into three groups using simple block randomization.\n\n* Group A will receive a combination of clindamycin and a retinoid, applied thinly to the entire facial area once daily at night.\n* Group B will receive a combination of clindamycin, a retinoid, and dexamethasone, with the same method of application as Group A.\n* Group C will receive 10% SM-hUCMSC secretome gel, applied thinly to acne-affected areas twice daily (morning and night).",[28],[159,224,225,226,227],"Clindamycin","Dexamethasone","Retinoid","Secretome","2026-03-28",{"date":230,"type":33},"2026-04-01",{"date":232,"type":22},"2026-04-18",{"date":234,"type":22},"2028-01-18",{"name":236,"class":40},"Yohanes Firmansyah, dr, MH, MM",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":74},"100629454","early-phase-1-efficacy-of-05-topical-timolol-eye-drops-in-the-treatment-of-post-inflammatory-erythema-following-acne-vulgaris-100629454","NCT07474883","Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris: A Comparative Study With Intense Pulsed Light (IPL)","Inclusion Criteria: Participants must meet all of the following criteria:\n\n* Age ≥ 12 years with a history of acne vulgaris.\n* Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris.\n* Willing and able to provide informed consent (or assent with parental\u002Fguardian consent if under 18 years of age).\n\nExclusion Criteria:\n\n* Refusal to participate or inability to comply with study procedures (examinations, treatment, follow-up visits), or loss to follow-up.\n* Presence of post-inflammatory hyperpigmentation (PIH) at the study site that may interfere with accurate assessment of erythema.\n* Presence of other dermatologic conditions affecting the treatment area (e.g., atopic dermatitis, rosacea, lupus erythematosus).\n* Known hypersensitivity or adverse reaction to timolol or other beta-adrenergic receptor blockers.\n* Pregnant or breastfeeding women.\n* History of cardiovascular or respiratory conditions contraindicating beta-blocker use (e.g., asthma, atrioventricular block, bradycardia \\\u003C50 beats per minute, hypotension).\n* Use of other topical medications or cosmetic products (except sunscreen) on the study area during the study period.",{"count":21,"type":22},[25],"Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation. Current treatment options include energy-based devices such as intense pulsed light (IPL); however, these modalities may be costly and require specialized equipment.\n\nTimolol, a non-selective beta-adrenergic receptor blocker, has demonstrated vasoconstrictive properties and has been used off-label in dermatology for vascular-related conditions. This study aims to evaluate the efficacy and safety of topical 0.5% timolol ophthalmic solution in improving post-inflammatory erythema secondary to acne vulgaris and to compare its clinical outcomes with those achieved by intense pulsed light (IPL) therapy.\n\nThis prospective comparative study will assess changes in erythema severity using standardized clinical evaluation and objective measurement tools over a defined treatment period. The findings may provide evidence for a cost-effective and accessible therapeutic alternative for managing post-acne erythema.",[248,28,249],"Post Inflammtory Erythema","Erythema","2026-03-26",{"date":230,"type":33},{"date":253,"type":22},"2026-03-09",{"date":255,"type":22},"2026-10-09",{"name":257,"class":40},"Pham Ngoc Thach University of Medicine",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":74},"100629378","phase-2-topical-5-spironolactone-gel-versus-01-adapalene-gel-for-acne-vulgaris-a-randomized-split-face-study-100629378","NCT07473895","Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study","Efficacy and Safety of Topical 5% Spironolactone Gel Nano-Formulation Versus 0.1% Adapalene Gel in the Management of Acne Vulgaris: A Split-Face Study","Inclusion Criteria:\n\nAge: 18-45 years old.\n\n* Patients with mild to moderate bilateral acne vulgaris on the face.\n* Presence of non-inflammatory acne (open and closed comedones).\n* Presence of inflammatory papules and pustules.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Patients taking oral contraceptive pills or any hormonal treatment.\n* Patients who were using topical or systemic medications for acne in the last two months prior to starting therapy.\n* Patients who had received laser resurfacing, chemical peeling, mesotherapy, or any similar facial interventions.",{"count":266,"type":22},40,[220],"Acne vulgaris is one of the most common dermatological conditions affecting adolescents and young adults. It results from multiple pathogenic factors, including increased sebum production, follicular hyperkeratinization, colonization by Cutibacterium acnes, and inflammation. Topical retinoids such as adapalene are widely used as first-line therapy; however, they may cause irritation and are not always effective in all patients. Recently, topical antiandrogen therapies such as spironolactone have gained attention because of their ability to reduce sebum production and improve acne lesions.\n\nThis study aims to evaluate the efficacy and safety of a topical 5% spironolactone gel nano-formulation compared with 0.1% adapalene gel in the treatment of acne vulgaris. A split-face study design will be used in which each participant will receive spironolactone gel on one side of the face and adapalene gel on the other side. This design allows each participant to serve as their own control and helps reduce variability in treatment response.\n\nParticipants diagnosed with acne vulgaris will be enrolled and treated for a defined follow-up period. Clinical assessment will be performed at baseline and during scheduled follow-up visits to evaluate improvement in acne lesions and monitor possible adverse effects. The primary outcomes will include changes in acne lesion counts and clinical severity scores. Safety and tolerability of both treatments will also be assessed.\n\nThe results of this study may provide evidence regarding the effectiveness of topical spironolactone nano-formulation as a potential alternative or adjunct therapy for acne vulgaris.",[28],[159,271,272,273,274,275,276,60,277],"Spironolactone","Adapalene","Topical therapy","Split-face study","Antiandrogen thearapy","Nano-Formulation","Acne treatment","2026-03-15",{"date":280,"type":33},"2026-03-17",{"date":203,"type":22},{"date":283,"type":22},"2026-12",{"name":285,"class":40},"Assiut University",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100628104","phase-3-1-clascoterone-cream-for-the-treatment-acne-vulgaris-100628104","NCT07457294","1% Clascoterone Cream for the Treatment Acne Vulgaris","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of 1% Clascoterone Cream in the Treatment of Acne Vulgaris","Inclusion Criteria:\n\n* Participants who are able to understand and comply with the protocol, voluntarily participate in the study, and sign the written informed consent form (ICF); for a participant aged \\\u003C18 years, the written ICF must be co-signed by the minor participant and a parent or legal guardian based on informed consent;\n* Age ≥12 years at the time of ICF signing, regardless of gender;\n* Diagnosis of moderate to severe acne vulgaris (including the nose) at screening and randomization, with an IGA score of 3 or 4, and facial lesions meeting the following criteria: 30-75 inflammatory lesions (papules, pustules, and nodules) and 30-100 non-inflammatory lesions (open and closed comedones);\n* Participants have used the same brand and type of skin and hair care products for at least 2 weeks prior to randomization and agree to continue the current products and regimen during the study period;\n* Female participants of childbearing potential (and their male partners) and male participants (and their female partners) must use highly effective contraception throughout the study period and for at least 3 months after the last dose of the study drug . Participants must have no plans for conception, sperm donation, or egg donation throughout the study period and for at least 3 months after the last dose of the study drug.\n\nExclusion Criteria:\n\n* Participants have more than 2 facial nodules at screening or randomization;\n* Participants have facial cysts at screening or randomization;\n* Participants have conditions at screening or randomization, which may interfere with the investigator's clinical assessments, including but not limited to: 1) Other facial dermatoses: specific types of acne (e.g., nodulocystic acne, acne conglobata, acne fulminans, etc.), secondary acne (e.g., drug-induced acne, mechanical acne, occupational acne, chloracne, etc.), or other facial rashes due to different conditions (e.g., rosacea, seborrheic dermatitis, solar dermatitis, lupus miliaris disseminatus faciei, psoriasis, eczema, etc.); 2) Facial skin or hair conditions that may interfere with clinical assessments (e.g., prominent beard, sideburns, whiskers, etc.);\n* Participants have systemic diseases with associated skin lesions: e.g., inflammatory bowel disease (Crohn's disease and ulcerative colitis), SAHA syndrome (seborrhea-acne-hirsutism-androgenetic alopecia syndrome), PCOS syndrome (polycystic ovary syndrome), SAPHO syndrome (synovitis-acne-pustulosis-hyperostosis-osteomyelitis), PAPA syndrome (pyogenic sterile arthritis-pyoderma gangrenosum-acne syndrome), hyperandrogenism-insulin resistance-acanthosis nigricans syndrome, congenital adrenal hyperplasia, etc.;\n* Prior use of the topical acne medications or therapies or Use of the systemic medications；\n* Use of skin care products with anti-acne efficacy within 2 weeks prior to randomization;\n* Participants have any serious or unstable medical condition that, in the investigator's judgment, may affect the participant's safety during the study and\u002For impede study completion, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, or psychiatric disorders.",{"count":294,"type":22},692,[88],"This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.\n\nTarget population: Participants aged ≥12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.\n\nTreatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily (morning and evening) for 12 weeks.",[28],"2026-03-03",{"date":253,"type":33},{"date":301,"type":22},"2026-05-04",{"date":303,"type":22},"2029-02-07",{"name":305,"class":152},"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":109,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":74},"100627478","phase-1-a-study-to-evaluate-efficacy-and-safety-of-hb0043-in-aadult-patients-with-moderate-to-severe-acne-vulgaris-100627478","NCT07449156","A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.","A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Acne Vulgaris (AV).","Inclusion Criteria:\n\n\\- 1. Understand the research procedure of this study and provide written informed consent; 2. Male or female, age 18 years or greater; 3. Diagnosed with mild to moderate facial acne vulgaris; 4. Throughout the study period, participants must refrain from using concomitant acne therapies.\n\n5\\. Acceptance by the patient, of childbearing age, to use safe contraceptive methods throughout the study, including 3 months of follow-up.\n\nExclusion Criteria:\n\n* 1\\. Participants with known hypersensitivity to HB0043 or any of its excipients; 2. Those with facial skin or hair conditions, or with facial skin damage or abnormality that may interfere with clinical assessment.\n\n  3\\. Participant has any facial skin disease other than common acne. 4. Presence of other active autoimmune diseases, including but not limited to psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and uveitis; 5. Participant has any other active skin disease or condition that may interfere with the assessment of acne vulgaris; 6. History of lymphoproliferative disorders or any known malignancy within five years prior to the Screening Visit (excluding treated and cured cutaneous squamous cell carcinoma, basal cell carcinoma, carcinoma uterine in situ, or intraductal breast cancer in situ); 7. History of recurrent or recent serious infection; 8. Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection; 9. Pregnant or lactating women; 10. Any reason why, in the opinion of the investigator, the patient should not participate.",{"count":314,"type":22},21,[219,220],"The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.",[28],"2026-02-27",{"date":320,"type":33},"2026-03-04",{"date":322,"type":22},"2026-03-27",{"date":324,"type":22},"2027-03-27",{"name":326,"class":152},"Shanghai Huaota Biopharmaceutical Co., Ltd.",{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100625374","evaluation-of-topical-dutasteride-as-a-potential-new-therapy-for-facial-acne-vulgaris-versus-the-triple-combination-therapy-clindamycin-phosphate-12-benzoyl-peroxide-31-and-adapalene-015-gel-100625374","NCT07421804","Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","Clinical and Microbiological Evaluation of Topical Dutasteride as a Potential New Therapy of Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","Inclusion Criteria:\n\n* Patients with facial acne vulgaris older than 18 years.\n\nExclusion Criteria:\n\n* · Unrealistic expectations.\n\n  * Unable to follow up.\n  * Severe and nodulocystic AV.\n  * Patients on topical treatment for AV (4 weeks before enrollment) and on systemic treatment for AV (3 months before enrollment).\n  * Patients on any systemic medication 3 months before enrollment.\n  * Suspicion of malignancy, including prostate cancer\n  * History of infertility or difficulty in fathering children.\n  * Pregnancy \\& lactation.\n  * Planning to become pregnant during study period or 6 months after ending treatment\n  * Patients with any concomitant dermatologic or systemic illness.",{"count":111,"type":22},[165],"Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience emotional distress, lower self-esteem and anxiety disorders .\n\nAcne Vulgaris is a chronic inflammatory skin condition affecting the pilosebaceous units that leads to the development of different skin lesions such as comedones, papules, pustules, nodules and cystic lesions .",[28],"2026-02-12",{"date":340,"type":33},"2026-02-19",{"date":203,"type":22},{"date":343,"type":22},"2028-04",{"name":285,"class":40},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":19,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":354,"briefSummary":355,"conditions":356,"keywords":357,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":4},"100623085","phase-4-metronidazole-2-gel-versus-clindamycin-1-gel-for-moderate-acne-vulgaris-100623085","NCT07392047","Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","Comparison Of The Efficacy Of 2% Metronidazole Gel Versus 1% Clindamycin Gel In The Treatment Of Moderate Acne Vulgaris","METROCLIN","Inclusion Criteria\n\nAdults aged 18-35 years of either sex.\n\nClinical diagnosis of moderate acne vulgaris, defined as a Modified Global Acne Grading System (mGAGS) score of 45-80.\n\nNot currently using any other anti-acne treatment (topical or systemic).\n\nExclusion Criteria\n\nPregnant or lactating women.\n\nSevere acne vulgaris, defined as an mGAGS score \\>80.\n\nKnown hypersensitivity\u002Fallergy to metronidazole or clindamycin (or any component of the study gels).\n\nAny other dermatologic condition affecting the face that may interfere with assessment of acne severity or treatment response.",{"count":21,"type":22},[53],"Acne vulgaris is a common inflammatory skin disorder. This randomized controlled trial (RCT) will compare the efficacy and safety of 2% metronidazole gel versus 1% clindamycin gel in adults with moderate acne vulgaris at Jinnah Postgraduate Medical Centre (JPMC), Karachi. Sixty eligible participants (18-35 years) will be enrolled using consecutive sampling and randomized in a 1:1 ratio using blocked randomization. Participants will apply the assigned gel as a thin layer twice daily for 12 weeks. Acne severity will be assessed using the Modified Global Acne Grading System (mGAGS) at baseline and at weeks 4, 8, and 12. The primary outcome is the proportion of participants achieving at least a 50% reduction from baseline in total mGAGS score at week 12. Local adverse effects (e.g., erythema, itching, irritation) will be recorded at each follow-up visit.",[28],[358,359,360,361,362],"Moderate acne","Metronidazole gel","Clindamycin gel","Topical antibiotic","Modified Global Acne Grading System","2026-02-05",{"date":365,"type":33},"2026-02-06",{"date":367,"type":22},"2026-02",{"date":369,"type":22},"2026-08",{"name":371,"class":73},"Jinnah Postgraduate Medical Centre",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":109,"sex":17,"minAge":48,"maxAge":215,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":4},"100619497","phase-2-safety-efficacy-and-pharmacokinetic-characteristics-of-kr230109-cream-in-facial-acne-vulgaris-100619497","NCT07345390","Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","A Multicenter, Double-blind, Placebo-parallel-controlled Phase Ⅱ Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 in Patients With Acne Vulgaris","Inclusion Criteria:\n\n1. Age between 18 and 40 years old (as of the time of signing the informed consent form), regardless of gender;\n2. Patients clinically diagnosed with mild to moderate facial acne vulgaris (refer to the \"Chinese Acne Treatment Guidelines\" 2019 revised edition), and with an overall facial IGA (Investigator Global Assessment) score of 2 to 3 by the study doctor;\n3. Baseline requirements: For patients with mild to moderate acne, the count of facial inflammatory lesions (papules and\u002For pustules) should be \\>=10 and \\\u003C=40; the count of non-inflammatory lesions (open and\u002For closed comedones) should be \\>=20 and \\\u003C=60; no facial nodules should exist;\n4. Participants must be willing to use only non-acne-treating skin care products during the trial and comply with the precautions required by the protocol;\n5. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent form, and be able to complete the entire trial process as required;\n6. From the time of signing the informed consent form to 3 months after the last administration, female participants of childbearing age or male participants whose partners are of childbearing age must agree and be able to take effective contraceptive measures, such as avoiding sexual activity or using reliable contraceptive methods like condoms or intrauterine devices.\n\nExclusion Criteria:\n\n1. Those known to be allergic to KR230109 or drugs with the same mechanism of action such as tazarotene, adapalene, or any of their components;\n2. Those with a history of any serious clinical systemic diseases or surgeries, such as diseases of the circulatory system, nervous system, hematological system, immune system, or mental system;\n3. Those with concurrent other obvious skin diseases at the affected area that may affect the clinical evaluation of the researchers or require concurrent treatment, such as solar dermatitis, psoriasis, seborrheic dermatitis, rosacea, eczema, severe acne, and extremely severe acne (such as conglobate acne, fulminant acne, etc.);\n4. Those with secondary acne, such as occupational acne and acne caused by corticosteroids;\n5. Those with facial skin or hair conditions that may interfere with clinical assessment (such as significant beards, sideburns, or mustaches);\n6. Those who plan to use any adjunctive therapies or concomitant treatments for acne during the trial;\n7. Those who have used acne-specific functional skin care products within one week before the start of treatment;\n8. Those who have used topical retinoids, antibiotics, corticosteroids, or other topical acne treatments on the face within two weeks before the trial;\n9. Those who have taken oral retinoids, antibiotics, corticosteroids (including intramuscular or intralesional injections, except for stable use of inhaled, intranasal, or intraocular corticosteroids for the treatment of underlying diseases and without impact on acne treatment), spironolactone, or other acne medications within four weeks before the trial;\n10. Those who have undergone physical or chemical acne treatments within four weeks before the trial;\n11. Those who have participated in other clinical trials and used trial drugs or medical devices within 90 days before screening or plan to participate in other clinical trials during the trial;\n12. Those whose vital signs, physical examinations, laboratory tests (blood routine, urine routine, blood biochemistry), electrocardiograms, etc., are abnormal and have clinical significance as assessed by the researchers and may affect the evaluation of this trial;\n13. Those who are positive for hepatitis B surface antigen, hepatitis C antibody, syphilis-specific antibody, or human immunodeficiency virus antibody;\n14. Pregnant or lactating women or those with positive blood or urine pregnancy tests;\n15. Those who need prolonged or excessive exposure to sunlight, such as sunbathing;\n16. Those with a history of alcohol abuse or drug abuse;\n17. Those who, in the opinion of the researchers, have poor compliance, or have conditions that may interfere with the study outcome, or those who, in the opinion of the researchers, have any other conditions that make them unsuitable for participation in this clinical trial.",{"count":380,"type":22},180,[220],"This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris",[28],"2026-01-08",{"date":386,"type":33},"2026-01-15",{"date":388,"type":22},"2026-01-10",{"date":390,"type":22},"2026-11-30",{"name":392,"class":152},"Jiangxi Kvvit Pharmaceutical Co., Ltd.",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":215,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":74},"100597298","cold-atmospheric-plasma-for-moderate-to-severe-acne-vulgaris-study-100597298","NCT07056673","Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study","Efficacy and Safety of Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris: a Multicentre, Randomised, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* Aged 18-40 years;\n* Clinically diagnosed with acne vulgaris, with moderate to severe disease (Pillsbury grade III or IV, lesion count ≥50);\n* Will agree to use effective contraception during the treatment period;\n* Will sign a written informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Known allergy to any active component of CAP;\n* Use of systemic antibiotics within 4 weeks prior to enrollment;\n* Presence of dyslipidemia or other severe systemic diseases;\n* Participation in other clinical trials within the past 3 months or currently enrolled in another clinical trial.",{"count":401,"type":22},220,[165],"Acne vulgaris is a common, chronic inflammatory skin disease with complex pathogenesis and limited therapeutic options, especially for moderate-to-severe cases. Standard treatments-including topical and oral agents-are often constrained by side effects, antimicrobial resistance, and treatment resistance. Cold atmospheric plasma (CAP), a novel technology that generates reactive oxygen and nitrogen species, has demonstrated antimicrobial and tissue-regenerative properties in dermatology, but robust clinical evidence in acne management remains scarce. Existing data suggest promising efficacy and safety, yet its use in moderate-to-severe acne vulgaris has not been adequately investigated. This study aims to evaluate the efficacy and safety of two self-developed CAP devices as a potential innovative therapy for moderate-to-severe acne vulgaris.",[28],[159,406],"Cold atmospheric plasma","2025-12-30",{"date":409,"type":33},"2026-01-02",{"date":411,"type":33},"2025-07-26",{"date":413,"type":22},"2026-12-20",{"name":415,"class":40},"Shenyang Medical College",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":109,"sex":17,"minAge":161,"maxAge":215,"enrollmentInfo":423,"targetDuration":4,"studyType":425,"phases":4,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100612230","evaluation-of-serum-ceramides-c16-c24-and-sphingosine-1-phosphate-s1p-in-patients-with-acne-vulgaris-100612230","NCT07250880","Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris","CER-S1P-ACNE","Inclusion Criteria:\n\n* For Case Group\n\nThis group will consist of (40) patients :\n\n* Both males and females aged 15-40 years.\n* Mild, Moderate, severe and very severe cases will be included. 5\n\nFor Control Group:\n\n• This group will consist of age- and sex-matched (40) healthy volunteers.\n\nExclusion Criteria:\n\n* Presence of any dermatological condition other than acne vulgaris (for cases).\n\n  * Use of systemic or topical treatment such as isotretinoin or antibiotics within the last 3 months.\n  * Pregnancy or lactation.\n  * History of lipid-lowering therapy or supplements affecting ceramide or sphingolipid metabolism.",{"count":424,"type":22},80,"OBSERVATIONAL","Acne vulgaris is a common chronic inflammatory skin disorder that affects adolescents and young adults. Recent research has shown that lipid mediators, including ceramides and sphingolipids, play an important role in maintaining skin barrier function and inflammation.\n\nThis study aims to evaluate the serum levels of ceramide C16, ceramide C24, and sphingosine-1-phosphate (S1P) in patients with acne vulgaris and compare them to healthy controls. The goal is to explore their possible role in the pathogenesis and severity of acne. Blood samples will be collected from participants, and quantitative analysis will be performed using liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS).",[28],"2025-11-18",{"date":430,"type":33},"2025-11-26",{"date":432,"type":22},"2025-11",{"date":434,"type":22},"2026-09",{"name":436,"class":40},"Sohag University",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":74},"100607273","phase-3-a-study-to-compare-the-efficacy-safety-and-pharmacokinetics-of-trifarotene-50-mcgg-cream-in-chinese-subjects-with-acne-vulgaris-100607273","NCT07186413","A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg\u002Fg Cream in Chinese Subjects With Acne Vulgaris","A Multicenter, Randomized, Double-blinded, Parallel-group, Vehicle-controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg\u002Fg Cream in Chinese Subjects With Acne Vulgaris","AKLIEF","Inclusion Criteria:\n\nParticipants must meet the following criteria to be included in the study:\n\n1. Male or female Chinese participants aged 9 years or older at the screening visit.\n2. A minimum of 20 inflammatory lesions and 25 non-inflammatory lesions on the face at Screening and Baseline.\n3. Facial acne vulgaris severity grade 3 (moderate) on the IGA scale at Screening and Baseline.\n4. A minimum of 20 inflammatory lesions and 20 non-inflammatory lesions but no more than 100 non-inflammatory lesion counts on the trunk (shoulders, upper back, and upper anterior chest) reachable for self-application of investigational product by the participant at Screening and Baseline (optional criterion for participant between 9 and 11 years of age).\n5. Acne vulgaris severity grade 3 (moderate) on the PGA scale at Screening and Baseline visits on trunk (shoulders, upper back and upper anterior chest) reachable for self-application of investigational product by the participant (optional criterion for participants between 9 and 11 years of age).\n6. Female participants of non-childbearing potential, i.e., premenstrual, or postmenopausal. Postmenopausal participants must meet one criterion at Screening:\n\n   * Absence of menstrual bleeding for 1 year before screening with no other medical reason, confirmed with follicle-stimulating hormone level in the postmenopausal range.\n   * Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before Screening.\n7. Female participants of childbearing potential (i.e., fertile, after menarche and until becoming postmenopausal unless permanently sterile) must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test (UPT) at the baseline visit (with a sensitivity of 25 international units per litre \\[IU\u002FL\\] or less). They must use at least 1 adequate and approved method of contraception throughout the study and for 1 month after the last dose of investigational product.\n8. Premenstrual participants who start menses during the study must use at least 1 adequate and approved method of contraception throughout the study and for 1 month after the last dose of investigational product.\n9. Willing and able to comply with all the time commitments and procedural requirements of the clinical study protocol.\n10. Understands and signs an informed consent form (ICF) at the screening visit, before any investigational procedures are performed.\n11. Participants who are younger than 18 years of age and whose parent\u002Flegal representative is willing\u002Fable to comply with the study requirements and understand\u002Fsign the ICF at the screening visit, before any investigational procedures are performed, will sign the assent ICF at the screening visit.\n12. At selected clinical sites: If a participant who is 18 years of age or older at the screening visit and agrees to participate in study photographs, verified by dating and signing a separate approved photography ICF. For participants younger than 18 years of age, an assent photography ICF signed by the participant in conjunction with a photography ICF signed by the parents(s)\u002Flegal representative at the screening visit.\n13. Participant is informed of terms pertaining to personal information protection and privacy and is willing to share personal information and data, in accordance with local regulations.\n\nExclusion Criteria:\n\nParticipants meeting the following criteria at the screening or baseline visits are ineligible to participate in this study:\n\n1. Pregnant women (positive serum pregnancy test result at the screening visit or positive UPT at the baseline visit), breastfeeding women, or women planning a pregnancy during the study or within 1 month after the last investigational product application.\n2. Severe forms of acne (e.g., acne conglobata, acne fulminans) or secondary acne form (e.g., chloracne, drug-induced acne) at the screening and baseline visits.\n3. More than 1 nodule on the face at the screening and baseline visits.\n4. More than 1 nodule on the trunk at the screening and baseline visits.\n5. Any acne cyst on the face at the screening and baseline visits.\n6. Any acne cyst on the trunk at the screening and baseline visits.\n7. Facial or truncal hair that may interfere with the study assessments according to investigator's judgment.\n8. Abnormal pigmentation, wound, scar, or tattoo on the face or on the shoulders, upper back, or chest that may interfere with the study assessments according to investigator's judgment.\n9. Any uncontrolled or serious disease or any medical or surgical condition that may interfere with the interpretation of the study results and\u002For put the participant at significant risk according to investigator's judgment.\n10. Abnormal laboratory test results at the screening visit (hematology, comprehensive metabolic panel, and urinalysis) judged as clinically significant by the investigator (to be checked before the baseline visit), which may interfere with the interpretation of the study results and\u002For put the participant at significant risk (e.g., elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (\\> 3 × upper limit of normal \\[ULN\\])).\n11. Known allergies or hypersensitivities to any component of the formulation of the investigational products (trifarotene 50 mcg\u002Fg cream or vehicle cream; see Investigator's Brochure).\n12. Previously participated in any trifarotene cream clinical study.\n13. Current participation in any other clinical study of a drug or device OR past participation within 30 days before the baseline visit.\n14. Alcohol or drug abuse or substance dependence within 12 months before the screening visit.\n15. Inability or unwillingness to undergo multiple venipunctures because of poor tolerability or venous access.\n16. Loss of over 500 mL of blood or blood donation within the last 3 months before the screening visit.\n17. Having received prohibited medication or treatment during the study.\n18. Exposure to excessive ultraviolet (UV) radiation within 1 month before the baseline visit.\n19. Unwillingness to avoid excessive or prolonged exposure to UV light (i.e., occupational exposure to the sun, sunbathing, tanning bed use, phototherapy) throughout the study.\n20. Any drug that in the opinion of the investigator may interfere with the study assessments or exacerbate acne, i.e., lithium, halogens, haloperidol, hydantoin, phenobarbital, Vitamin B12, androgens.\n21. Unwillingness to refrain from prohibited medication during the clinical study as defined by protocol.\n22. Participant vulnerability (such as freedom deprivation, mental disease, those incapable of giving consent) as defined in Section 1.61 of the International Council for Harmonization Guideline for Good Clinical Practice (GCP).\n23. More than 1 participant sharing the same household.\n24. Clinical site personnel, close relatives of the clinical site personnel (e.g., parents, children, siblings, or spouse), employees, or close relatives of employees of the Sponsor company.",{"count":446,"type":22},561,[88],"The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg\u002Fg) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.",[28],{"date":451,"type":33},"2025-11-21",{"date":453,"type":33},"2025-09-23",{"date":455,"type":22},"2026-12-31",{"name":457,"class":152},"Galderma R&D",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":470,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":74},"100600799","phase-4-efficacy-and-safety-of-adapalene-gel-and-hyaluronic-acid-versus-adapalene-gel-alone-in-mild-to-moderate-acne-vulgaris-100600799","NCT07102186","Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris","Comparing the Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris: An Open-label Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients with mild to moderate acne vulgaris who have not used topical retinoids or systemic acne treatments within the past 3 months will be included.\n\nExclusion Criteria:\n\n* patients with severe acne, nodulocystic acne, secondary infections, known hypersensitivity to adapalene or hyaluronic acid, pregnant, or lactating individuals.",{"count":466,"type":22},120,[53],"Acne vulgaris affects around 85% of adolescents and young adults. Adapalene, a topical retinoid, is a common treatment but often causes irritation, leading to poor adherence. Hyaluronic acid (HA), known for its hydrating and anti-inflammatory properties, may help reduce these side effects.\n\nThis prospective, open-label, randomized controlled trial compares adapalene 0.1% gel combined with HA serum versus adapalene alone over 8 weeks in patients with mild to moderate acne. Key outcomes include acne lesion reduction, incidence and severity of side effects (erythema, dryness, scaling, stinging\u002Fburning, pruritus), and skin hydration assessed through the skin turgor test. Acne severity will be measured using the Acne Severity Index (ASI) and Investigator's Global Assessment (IGA) scale.\n\nThe study anticipates better efficacy, reduced irritation, and improved skin hydration with the combination therapy. Ethical approval was obtained, and informed consent will be secured from all participants.",[28],[471,472,473,474],"acne vulgaris","adapalene","Hyaluronic acid","Topical Retinoids","2025-07-28",{"date":477,"type":33},"2025-08-03",{"date":479,"type":33},"2025-07-21",{"date":481,"type":22},"2025-10-21",{"name":483,"class":40},"Badr University",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":492,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":74},"100547094","phase-3-efficacy-and-safety-of-clascoterone-cream-1-in-facial-acne-vulgaris-100547094","NCT06403501","Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris","A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris","Inclusion Criteria:\n\n* Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);\n* Male or female, 12 years of age or older;\n* Subjects aged 18 years or older are required to provide informed consent and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.\n\nExclusion Criteria:\n\n* Subject has greater than two (2) facial nodules;\n* Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;\n* Subject has used topical and systemic anti-acne medications or therapies;\n* Subject has received hormonal therapy for acne treatment;\n* Subject has used a skincare product with acne removal effect;\n* Subject has other serious underlying diseases such as mental illness or malignant tumors;\n* Subject has any of the clinically significant laboratory test indicators at screening;\n* Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;\n* Subject engaged in drug abuse or excessive alcohol intake;\n* Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;\n* Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;\n* Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;\n* Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.",{"count":294,"type":22},[88],"The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.",[28],[28],"2025-07-03",{"date":498,"type":33},"2025-07-09",{"date":500,"type":33},"2024-05-20",{"date":70,"type":22},{"name":305,"class":152},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":109,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":74},"100597714","correlation-between-acne-vulgaris-and-lipid-profile-among-young-adults-in-sohag-governorate-100597714","NCT07062081","Correlation Between Acne Vulgaris and Lipid Profile Among Young Adults in Sohag Governorate","Inclusion Criteria:\n\n* age- and sex-matched healthy volunteers, not taking any medicine, and having no personal or family history of acne.\n\nExclusion Criteria:\n\n* : reluctance to take part in the study, pregnancy or lactation\n\n  * intake of oral contraception or hormone therapy, history of taking any medications that affect lipid metabolism or oral isotretinoin\n  * and systemic diseases that affect the metabolism of lipids, such as uncontrolled diabetes, hypothyroidism, nephrotic syndrome, end-stage renal failure, HIV, familial hypercholesterolemia, and metabolic syndrome.",{"count":191,"type":22},[165],"Acne vulgaris is the most common skin condition affecting late adolescents worldwide.1 The prevalence of acne is said to be 85% in adults aged 12 to 25 years.2 Almost all teenagers between 15 and 17 years report having some degree of acne.3 Estimates of the lifetime occurrence of acne in the literature range from 0.1%4 to as high as 85.1%5 in the general population, depending on the age range, region, and method of sampling. Overall, acne is more common in women,8,9 but in some literature the prevalence is approximately equal in men and women.10,11",[28],"2025-07-02",{"date":515,"type":33},"2025-07-14",{"date":517,"type":22},"2025-08-01",{"date":519,"type":22},"2026-01-30",{"name":436,"class":40},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":109,"sex":17,"minAge":48,"maxAge":215,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":74},"100597123","assessment-of-serum-catestatin-level-in-acne-vulgaris-patients-100597123","NCT07054398","Assessment of Serum Catestatin Level in Acne Vulgaris Patients","Assessment of Serum Catestatin Level in Acne Vulgaris Patients Before and After Treatment With Oral Isotretinoin","Inclusion Criteria:\n\n* Healthy persons of both sexes with moderate and severe acne.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Immunocompromised patients.\n* Severe anemia.\n* History of chronic liver disease.\n* Hyperlipidemia\n* Non-inflammatory acne conditions.\n* History of neurologic disorders.\n* History of neoplastic disorders.\n* History of cardiac disease.\n* History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.\n* Cases with known hypersensitivity reaction to isotretinoin.",{"count":21,"type":22},[165],"Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults.\n\nCatestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.",[28],"2025-06-27",{"date":534,"type":33},"2025-07-08",{"date":536,"type":33},"2025-01-10",{"date":388,"type":22},{"name":539,"class":40},"Aswan University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":215,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":551,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":74},"100593487","early-phase-1-efficacy-of-dihydroartemisinin-for-treating-acne-vulgaris-100593487","NCT07007078","Efficacy of Dihydroartemisinin for Treating Acne Vulgaris","A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Acne Vulgaris","Inclusion Criteria:\n\n* Clinically diagnosed with acne vulgaris;\n* For female patients, no pregnancy plans within the next 6 months.\n\nExclusion Criteria:\n\n* Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;\n* Patients who have used topical medications for acne within the past 2 weeks;\n* Pregnant or breastfeeding women;\n* Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:\n\n• Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris.\n\nParticipants will:\n\n* Take DHA every day for 3 months\n* Visit the clinic once every month for checkups and tests",[28],[471,552],"dihydroartemisinin","2025-05-28",{"date":555,"type":33},"2025-06-05",{"date":557,"type":22},"2025-06",{"date":283,"type":22},{"name":560,"class":40},"Shanghai Zhongshan Hospital",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":4},"100571826","excimer-light-versus-blue-light-in-acne-100571826","NCT06725303","Excimer Light Versus Blue Light in Acne","Excimer Light Versus Blue Light in the Treatment of Inflammatory Acne, a Split Face Randomized Controlled Trial.","Inclusion Criteria:\n\n* Patients with mild to moderate inflammatory acne lesions\n\nExclusion Criteria:\n\n* Pregnancy during the first trimester\n\n  * Female patients with a medical history of PCO\n  * Topical and systemic treatment within the last month and systemic retinoids for 6 months\n  * Patients on systemic steroid treatment or hormonal therapy\n  * Severe systemic illness or malignancy\n  * Photosensitivity\n  * Scarring acne vulgaris","25 Years",{"count":570,"type":22},24,[165],"The aim is to assess the efficacy and safety of Excimer Light versus blue light in the treatment of inflammatory acne.",[28],"2025-05-10",{"date":576,"type":33},"2025-05-14",{"date":578,"type":22},"2025-06-01",{"date":580,"type":22},"2025-10-01",{"name":582,"class":40},"Cairo University",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":109,"sex":17,"minAge":48,"maxAge":215,"enrollmentInfo":590,"targetDuration":4,"studyType":425,"phases":4,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":595,"leadSponsor":597,"locationsCount":4},"100571825","dry-eye-disease-with-isotretinoin-isotretinoin-100571825","NCT06725290","Dry Eye Disease With Isotretinoin ISOTRETINOIN","Digital Assessment of Dry Eye Diseases in Acne Vulgaris Patients Receiving Isotretinoin Therapy","Inclusion Criteria:\n\n* Moderate to severe acne on isotretinoin\n\nExclusion Criteria:\n\n* Occular diseases causing dry eye\n* Pregnant females",{"count":21,"type":22},"The study aims to explore the effects of isotretinoin therapy on the dry eye parameters in acne vulgaris patients \\& determine if it is dose-dependent or not.",[28],{"date":576,"type":33},{"date":578,"type":22},{"date":596,"type":22},"2025-09-30",{"name":582,"class":40}]